期刊文献+

前列腺特异抗原<20ng/ml时不同前列腺穿刺方案的临床意义 被引量:3

下载PDF
导出
摘要 目的对前列腺特异抗原(PSA)<20ng/ml的患者进行扩大前列腺穿刺活检,从而评价扩大穿刺对PSA<20ng/ml前列腺癌筛选中的临床应用价值。方法采用"10+X"穿刺法检测51例,"6+X"穿刺法检测54例。应用配对卡方检验对"10+X"针法和"6+X"针法活检术对前列腺癌检出率进行比较。结果"6+X"针法检测出前列腺癌24例(24/54),"10+X"针法检测出前列腺癌35例(35/51),差异有显著性。前列腺癌组前列腺体积明显小于良性前列腺增生组,前列腺特异性抗原密度值显著高于良性前列腺增生组。结论在传统"6"针法的基础上,左右两侧外周带各2针,增加前列腺癌高发区域的穿刺数目,一定程度上增加了阳性穿刺率;选择"X"穿刺点为直肠指诊异常或超声下的低回声或可疑区域穿刺点,增加了前列腺癌可疑区域的活检,提高了前列腺癌的阳性率;"10+X"针法结合了增加前列腺癌高发区域的穿刺和前列腺癌可疑区域的活检,提高了前列腺癌的检出率。
作者 徐建平
出处 《中国临床医生杂志》 2014年第8期67-69,共3页 Chinese Journal For Clinicians
  • 引文网络
  • 相关文献

参考文献7

二级参考文献47

  • 1赵耀瑞,徐勇,张殿举,畅继武,张淑敏,史启铎,孙光,韩瑞发,姚庆祥,马腾骧.血清PSA、PSAD和PSAT在前列腺穿刺活检中的意义[J].中华泌尿外科杂志,2005,26(9):622-625. 被引量:35
  • 2王可兵,高新.前列腺癌的免疫治疗[J].国际泌尿系统杂志,2006,26(2):179-182. 被引量:2
  • 3许勇,杨勇,洪宝发,卢锦山.放射性粒子组织间植入治疗局限性前列腺癌[J].临床泌尿外科杂志,2007,22(3):195-196. 被引量:5
  • 4Nag S,Beyer D,Friedland J,et al.American Brachytherapy Society recommendations for transperineal permanent brachytherapy of prostate cancer[J].Int J Radiat Oncol Bios Phys,1999,44:789-799.
  • 5G D Wilson,Y Hasan,C Mitchell,et al.High Dose Rate Brachytherapy Boost for Prostate Cancer:Is More BED better?[J].I J Radiation Oncology d Biology d Physics,2007,67(3):316.
  • 6Yoshiya Yamada,Sudershan Bhatia,Marco Zaider,et al.Favorable clinical outcomes of three-dimensional computer-optimized high-dose-rate prostate brachytherapy in the management of localized prostate cancer[J].Brachytherapy,2006,5:157-164.
  • 7Hiromichi Ishiyamaa,Masashi Kitanoa,Takefumi Satohb,et al.Difference in rectal dosimetry between pre-plan and post-implant analysis in transperineal interstitial brachytherapy for prostate cancer[J].Radiotherapy and Oncology,2006,78:194-198.
  • 8Catherine Buron,PH D,Beatrice Le Vu,et al.Brachytherapy versus prostatectomy in localized prostate cancer:results of a French multicenter prospective medico-economic study[J].Int J Radiation Oncology Biol Phys,2007,67(3):812-822.
  • 9Pasteau O,Degrais P.The radium treatment of cancer of the prostate[J].Arch R oentgen Ray,1914,2(8):396.
  • 10Barringer BS.Radium in the treatment of carcinoma of the bladder a ndp rostate[J].J AMA,1917,6(8):1227.

共引文献20

同被引文献29

  • 1张家庭,常江平,李泉水,田平,粟晖,董常峰.经直肠超声及其穿刺活检对前列腺增生与前列腺癌的鉴别诊断价值[J].临床超声医学杂志,2004,6(3):164-166. 被引量:3
  • 2De Nunzio C, Kramer G, Marberger M, et al. The controversial re- lationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation [ J ]. Eur Urol, 2011,60 ( 1 ) : 106-117.
  • 3Nickel JC, True LD, Krieger JN, et al. Consensus development of a histopathological classification system for chronic prostatic inflamma- tion[J]. BJU Int, 2001,87(9) :797-805.
  • 4De MarzoAM, Platz EA, Epstein JI, et al. A working group classifi- cation of focal prostate atrophy lesions [ J ]. Am J Surg Pathol, 2006, 30(10) :1281-1291.
  • 5Okada F. Inflammation-related carcinogenesis: current findings inepidemiological trends, causes and mechanisms [ J ]. Yonago Acta Med, 2014,57(2) :55-72.
  • 6Liu X, Goldstein AS. Inflammation promotes prostate differentiation [J]. Proc Natl Acad Sci USA, 2014,111(5) :1666-1667.
  • 7De Angulo A, Faris R, Cavazos D, et al. Age-related alterations in T-lymphocytes modulate key pathways in prostate tumorigenesis[ J]. Prostate, 2013,73(8) :855-864.
  • 8Davidsson S, Fiorentino M, Andren O, et al. Inflammation, focal a- trophie lesions, and prostatic intraepithelial neoplasia with respect to risk of lethal prostate cancer [ J 3. Cancer Epidemiol Biomarkers Prev, 2011,20(10) :2280-2287.
  • 9Kryvenko ON, Jankowski M, Chitale DA, et al. Inflammation and preneoplastic lesions in benign prostate as risk factors for prostate cancer[ J]. Mod Pathol, 2012,25 (7) : 1023-1032.
  • 10Delongchamps NB, de la Roza G, Chandan V, et al. Evaluation of prostatitis in autopsied prostates--is chronic inflammation more asso- ciated with benign prostatic hyperplasia or cancer[ J]. J Urol, 2008, 179(5) :1736-1740.

引证文献3

二级引证文献34

;
使用帮助 返回顶部